Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07617272 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore

Study acronym: PARIS-BIO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer. Patients will receive Darolutamide monotherapy for 90-120 days prior to radical prostatectomy. The study aims to validate if the biomarker can identify patients who achieve Minimal Residual Disease (MRD) at the time of surgery.
Trial Details
NCT Number NCT07617272
Lead Sponsor Region Stockholm
Collaborators: Sahlgrenska University Hospital, Philips Intellectual Property & Standards, OHMX.bio, European Union, Bayer
Conditions
(from sponsor)		 Prostate Cancer (Adenocarcinoma)
Related terms Adenocarcinoma, Prostatic Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov